Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2015 Oct;25(10):749-53.
doi: 10.1016/j.nmd.2015.07.009. Epub 2015 Jul 17.

Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test

Marika Pane  1 , Lavinia Fanelli  1 , Elena Stacy Mazzone  1 , Giorgia Olivieri  1 , Adele D'Amico  2 , Sonia Messina  3 , Marianna Scutifero  4 , Roberta Battini  5 , Roberta Petillo  4 , Silvia Frosini  5 , Serena Sivo  1 , Gian Luca Vita  3 , Claudio Bruno  6 , Tiziana Mongini  7 , Elena Pegoraro  8 , Roberto De Sanctis  1 , Alice Gardani  9 , Angela Berardinelli  9 , Valentina Lanzillotta  6 , Adelina Carlesi  2 , Emanuela Viggiano  4 , Filippo Cavallaro  3 , Maria Sframeli  3 , Luca Bello  8 , Andrea Barp  8 , Flaviana Bianco  1 , Serena Bonfiglio  10 , Enrica Rolle  7 , Concetta Palermo  1 , Grazia D'Angelo  11 , Antonella Pini  10 , Elena Iotti  12 , Ksenija Gorni  13 , Giovanni Baranello  12 , Enrico Bertini  2 , Luisa Politano  4 , Maria Pia Sormani  14 , Eugenio Mercuri  15
Affiliations
Multicenter Study

Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test

Marika Pane et al. Neuromuscul Disord. 2015 Oct.

Abstract

The aim of this study was to establish the possible effect of glucocorticoid treatment on upper limb function in a cohort of 91 non-ambulant DMD boys and adults of age between 11 and 26 years. All 91 were assessed using the Performance of Upper Limb test. Forty-eight were still on glucocorticoid after loss of ambulation, 25 stopped steroids at the time they lost ambulation and 18 were GC naïve or had steroids while ambulant for less than a year. At baseline the total scores ranged between 0 and 74 (mean 41.20). The mean total scores were 47.92 in the glucocorticoid group, 36 in those who stopped at loss of ambulation and 30.5 in the naïve group (p < 0.001). The 12-month changes ranged between -20 and 4 (mean -4.4). The mean changes were -3.79 in the glucocorticoid group, -5.52 in those who stopped at loss of ambulation and -4.44 in the naïve group. This was more obvious in the patients between 12 and 18 years and at shoulder and elbow levels. Our findings suggest that continuing glucocorticoids throughout teenage years and adulthood after loss of ambulation appears to have a beneficial effect on upper limb function.

Keywords: Duchenne muscular dystrophy; Glucocorticoids; Non ambulant; PUL; Upper limb.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Baseline PUL scores in the shoulder (S), middle (M) and distal (D) domains, according to GC exposure.
Fig. 2
Fig. 2
Middle and distal 12-month PUL change decrease (%) according to GC exposure in the middle domain (in green) and in the distal domain (in blue).
See this image and copyright information in PMC

References

    1. Henricson E.K., Abresch R.T., Cnaan A. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve. 2013;48:55–67. - PMC - PubMed
    1. Bushby K., Connor E. Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. Clin Investig (London) 2011;1:1217–1235. - PMC - PubMed
    1. Lynn S., Aartsma-Rus A., Bushby K. Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy. Neuromuscul Disord. 2015;25:96–105. - PubMed
    1. Bushby K., Finkel R., Birnkrant D.J. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9:177–189. - PubMed
    1. Bushby K., Finkel R., Birnkrant D.J. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77–93. - PubMed

Publication types

Substances